Plus Therapeutics, Inc. (PSTV)

Over the past six months, Plus Therapeutics' stock has experienced significant volatility and a notable decline, with the share price dropping by 80.91% between February 4, 2025, and February 3, 2026. The company has not consistently beaten consensus EPS estimates, missing expectations in all of the last four reported quarters. On January 22, 2026, the stock price declined by 5.00% despite positive performance in the broader market. Short interest in Plus Therapeutics recently increased by 54.89%, indicating a decrease in investor sentiment. Despite recent stock performance, Plus Therapeutics has received a consensus rating of "Moderate Buy" from analysts, with an average price target of $5.80.

Based on the available information, there is no indication of significant demand seasonality for Plus Therapeutics, Inc.'s products and services. Demand for its products, once commercialized, would likely be driven by medical need rather than seasonal factors.

Plus Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology, focusing on developing targeted radiotherapeutics for difficult-to-treat cancers in adults and children. The company develops drugs that deliver targeted radiation directly to cancer cells while minimizing harm to healthy tissues, utilizing nanoliposomes and microspheres for precise delivery of therapeutic radioisotopes. Its lead candidate, 90Y-HP-DO3A, is in Phase 2 development for recurrent high-grade gliomas. The rhenium-based nanoliposome program is under investigation for diffuse intrinsic pontine glioma, brain metastases, and other solid tumors. REYOBIQ™ is a radiotherapeutic candidate for central nervous system cancers, delivered locally using methods like convection-enhanced delivery and intraventricular brain catheters. Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188RNL-BAM) is a next-generation radioembolization therapy being developed for various solid organ cancers. CNSide® is a commercial cerebrospinal fluid tumor cell enumeration diagnostic test for detecting metastatic CNS cancer.

Plus Therapeutics, Inc. is headquartered in Austin, Texas, with additional laboratories and state-of-the-art clean rooms located in Houston, Texas. The company conducts its clinical studies in collaboration with academic medical centers and contract research organizations across North America.

In the past year, Plus Therapeutics has maintained a "Moderate Buy" consensus rating from analysts, scoring higher than 51% of companies evaluated in the medical sector by MarketBeat's MarketRank™. The company's focus on addressing unmet needs in both adult and pediatric oncology through its targeted radiotherapeutics could contribute positively to its reputation. However, the significant increase in short interest indicates a decreasing investor sentiment, which can negatively impact brand perception in the financial community, and consistent negative earnings surprises may also contribute to a cautious view among some investors.

Plus Therapeutics, Inc. has 30 institutional owners and shareholders who have filed 13D/G or 13F forms, holding a total of 6,322,829 shares. Major institutional owners include Vanguard Group Inc, Altium Capital Management LP, and UBS Group AG. Individual insiders, including CEO Marc Hedrick, directly own 0.19% of the company's shares.